umbralisib Report issue

Small molecule Orphan Drug FDA Approved FDA Breakthrough Therapy FDA Accelerated Approval FDA

Active Ingredient History

NOW
  • Now
Umbralisib, sold under the brand name Ukoniq, is a medication for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). It is taken by mouth.   Wikipedia

  • SMILES: CC(C)Oc1ccc(cc1F)c2nn([C@@H](C)C3=C(C(=O)c4cc(F)ccc4O3)c5cccc(F)c5)c6ncnc(N)c26
  • InChIKey: IUVCFHHAEHNCFT-INIZCTEOSA-N
  • Mol. Mass: 571.56
  • ALogP: 6.66
  • ChEMBL Molecule:
More Chemistry
umbralisib

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue